cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.7850732
title: Comparison of visual fatigue caused by head-mounted display for virtual reality and two-dimensional display using objective and subjective evaluation

description: This study aimed to evaluate objective and subjective visual fatigue experienced before and after performing a visual task while using a head-mounted display for virtual reality (VR-HMD) and two-dimensional (2D) display. Binocular fusion maintenance (BFM) was measured using a binocular open-view Shack–Hartmann wavefront aberrometer equipped with liquid crystal shutters. Twelve healthy subjects performed the BFM test and completed a questionnaire regarding subjective symptoms before and after performing a visual task that induces low visually induced motion sickness (VIMS). BFM (<i>p</i> = .87) and total subjective eye symptom scores (<i>p</i> = .38) were not significantly different between both groups, although these values were significantly lower after the visual task than before the task within both groups (<i>p</i> &lt; .05). These findings suggest that visual fatigue after using a VR-HMD is not significantly different from that after using a 2D display in the presence of low-VIMS VR content. <b>Practitioner summary</b><b>:</b> Objective and subjective evaluation of visual fatigue were not significantly different with the use of a head-mounted display for virtual reality (VR-HMD) and two-dimensional display. These results should be valuable not only to engineers developing VR content but also to researchers involved in the evaluation of visual fatigue using VR-HMD. <b>Abbreviations:</b> VR: virtual reality; VR-HMD: head-mounted display for virtual reality; BFM: binocular fusion maintenance; BWFA: binocular open-view Shack–Hartmann wavefront aberrometer
DOI: 10.6084/m9.figshare.7850732.v2
title: Comparison of visual fatigue caused by head-mounted display for virtual reality and two-dimensional display using objective and subjective evaluation

description: This study aimed to evaluate objective and subjective visual fatigue experienced before and after performing a visual task while using a head-mounted display for virtual reality (VR-HMD) and two-dimensional (2D) display. Binocular fusion maintenance (BFM) was measured using a binocular open-view Shack–Hartmann wavefront aberrometer equipped with liquid crystal shutters. Twelve healthy subjects performed the BFM test and completed a questionnaire regarding subjective symptoms before and after performing a visual task that induces low visually induced motion sickness (VIMS). BFM (<i>p</i> = .87) and total subjective eye symptom scores (<i>p</i> = .38) were not significantly different between both groups, although these values were significantly lower after the visual task than before the task within both groups (<i>p</i> &lt; .05). These findings suggest that visual fatigue after using a VR-HMD is not significantly different from that after using a 2D display in the presence of low-VIMS VR content. <b>Practitioner summary</b><b>:</b> Objective and subjective evaluation of visual fatigue were not significantly different with the use of a head-mounted display for virtual reality (VR-HMD) and two-dimensional display. These results should be valuable not only to engineers developing VR content but also to researchers involved in the evaluation of visual fatigue using VR-HMD. <b>Abbreviations:</b> VR: virtual reality; VR-HMD: head-mounted display for virtual reality; BFM: binocular fusion maintenance; BWFA: binocular open-view Shack–Hartmann wavefront aberrometer
DOI: 10.6084/m9.figshare.7850684
title: MOESM2 of Plasma cell-free DNA: a potential biomarker for early prediction of severe dengue

description: Additional file 2. The demographic, laboratory and clinical details of all eligible study participants including their diagnosis and clinical course information.
DOI: 10.6084/m9.figshare.7850684.v1
title: MOESM2 of Plasma cell-free DNA: a potential biomarker for early prediction of severe dengue

description: Additional file 2. The demographic, laboratory and clinical details of all eligible study participants including their diagnosis and clinical course information.
DOI: 10.6084/m9.figshare.7850672
title: Additional file 1: of Formulation and evaluation of norcanthridin nanoemulsions against the Plutella xylostella (Lepidotera: Plutellidae)

description: Table S1. The performance of nanoemulsions with different cosurfactants. Table S2. Regression equation of NCTD against the 3rd-instar larvae of P. xylostella. Table S3. Oral toxicity of different surfactant-to-cosurfactant mass ratio (Smix) against the 3rd- instar larvae of P. xylostella (SOR =4:6). Table S4. Oral toxicity of different surfactant-to-cosurfactant mass ratio (Smix) against the 3rd- instar larvae of P. xylostella (SOR = 6:4). Table S5. Oral toxicity of different surfactant-to-cosurfactant mass ratio (Smix) against the 3rd- instar larvae of P. xylostella (SOR = 3:7). Figures.xlsx Sheet1 Fig. 1 Ternary phase diagrams of water/nonionic surfactant/triacetin systems at 25 °C (NE: nanoemulsion region). Figures.xlsx Sheet2 Fig. 2 Ternary phase diagrams of water/Cremophor EL-butanol (Smix)/triacetin systems at 25 °C (NE: nanoemulsion region). Figures.xlsx Sheet3 Fig. 3 Droplet size, size distribution and mortality rate (48 h) of triacetin/Cremophor EL/butanolt/water systems at 25 °C (triacetin: Smix = 5:5, water = 96 wt.%). Figures.xlsx Sheet4 Fig. 4 The effect of different surfactant-to-oil mass ratio (SOR) on the oral toxicity of NCTD-nanoemulsion (Smix = 1:1, NCTD 200 mg/L) against the third-instar of P. xylostella. (ZIP 31 kb)
DOI: 10.6084/m9.figshare.7850672.v1
title: Additional file 1: of Formulation and evaluation of norcanthridin nanoemulsions against the Plutella xylostella (Lepidotera: Plutellidae)

description: Table S1. The performance of nanoemulsions with different cosurfactants. Table S2. Regression equation of NCTD against the 3rd-instar larvae of P. xylostella. Table S3. Oral toxicity of different surfactant-to-cosurfactant mass ratio (Smix) against the 3rd- instar larvae of P. xylostella (SOR =4:6). Table S4. Oral toxicity of different surfactant-to-cosurfactant mass ratio (Smix) against the 3rd- instar larvae of P. xylostella (SOR = 6:4). Table S5. Oral toxicity of different surfactant-to-cosurfactant mass ratio (Smix) against the 3rd- instar larvae of P. xylostella (SOR = 3:7). Figures.xlsx Sheet1 Fig. 1 Ternary phase diagrams of water/nonionic surfactant/triacetin systems at 25 °C (NE: nanoemulsion region). Figures.xlsx Sheet2 Fig. 2 Ternary phase diagrams of water/Cremophor EL-butanol (Smix)/triacetin systems at 25 °C (NE: nanoemulsion region). Figures.xlsx Sheet3 Fig. 3 Droplet size, size distribution and mortality rate (48 h) of triacetin/Cremophor EL/butanolt/water systems at 25 °C (triacetin: Smix = 5:5, water = 96 wt.%). Figures.xlsx Sheet4 Fig. 4 The effect of different surfactant-to-oil mass ratio (SOR) on the oral toxicity of NCTD-nanoemulsion (Smix = 1:1, NCTD 200 mg/L) against the third-instar of P. xylostella. (ZIP 31 kb)
DOI: 10.6084/m9.figshare.7850648
title: Additional file 1: of Prevalence of injecting drug use in Estonia 2010â 2015: a capture-recapture study

description: Capture frequencies by gender, age group, county of residence, year, and registries. (XLSX 54 kb)
DOI: 10.6084/m9.figshare.7850654
title: Additional file 2: of Prevalence of injecting drug use in Estonia 2010â 2015: a capture-recapture study

description: Bayesian and maximum likelihood estimates of the total number of PWID for years 2010-2015. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.7850654.v1
title: Additional file 2: of Prevalence of injecting drug use in Estonia 2010â 2015: a capture-recapture study

description: Bayesian and maximum likelihood estimates of the total number of PWID for years 2010-2015. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.7850648.v1
title: Additional file 1: of Prevalence of injecting drug use in Estonia 2010â 2015: a capture-recapture study

description: Capture frequencies by gender, age group, county of residence, year, and registries. (XLSX 54 kb)
DOI: 10.6084/m9.figshare.7850630
title: Additional file 9: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S9. Results of prioritization according to criterion 4A. (XLSX 15 kb)
DOI: 10.6084/m9.figshare.7850630.v1
title: Additional file 9: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S9. Results of prioritization according to criterion 4A. (XLSX 15 kb)
DOI: 10.6084/m9.figshare.7850618
title: Additional file 7: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S7. Results of prioritization according to criterion 2. (XLSX 33 kb)
DOI: 10.6084/m9.figshare.7850624
title: Additional file 8: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S8. Results of prioritization according to criterion 3. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.7850612
title: Additional file 6: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S6. Results of prioritization according to criterion 1. (XLSX 30 kb)
DOI: 10.6084/m9.figshare.7850618.v1
title: Additional file 7: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S7. Results of prioritization according to criterion 2. (XLSX 33 kb)
DOI: 10.6084/m9.figshare.7850624.v1
title: Additional file 8: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S8. Results of prioritization according to criterion 3. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.7850606
title: Additional file 5: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S5. Ranks of analyzed genes. (XLSX 23 kb)
DOI: 10.6084/m9.figshare.7850612.v1
title: Additional file 6: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S6. Results of prioritization according to criterion 1. (XLSX 30 kb)
DOI: 10.6084/m9.figshare.7850597
title: Additional file 3: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S3. Lists of diseases comorbid to lymphedema. (XLSX 11 kb)
DOI: 10.6084/m9.figshare.7850600
title: Additional file 4: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S4. Values of betweenness centrality of nodes of lymphedema associative gene network. (XLSX 16 kb)
DOI: 10.6084/m9.figshare.7850606.v1
title: Additional file 5: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S5. Ranks of analyzed genes. (XLSX 23 kb)
DOI: 10.6084/m9.figshare.7850597.v1
title: Additional file 3: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S3. Lists of diseases comorbid to lymphedema. (XLSX 11 kb)
DOI: 10.6084/m9.figshare.7850600.v1
title: Additional file 4: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S4. Values of betweenness centrality of nodes of lymphedema associative gene network. (XLSX 16 kb)
DOI: 10.6084/m9.figshare.7850582
title: Additional file 1: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S1. Lists of genes associated with lymphedema. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.7850588
title: Additional file 2: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S2. Results of gene ontology enrichment analysis. (XLSX 14 kb)
DOI: 10.6084/m9.figshare.7850579
title: Additional file 14: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S14. Interactions of top 10 most promising candidate genes with genes/proteins associated with lymphedema. (XLSX 173 kb)
DOI: 10.6084/m9.figshare.7850582.v1
title: Additional file 1: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S1. Lists of genes associated with lymphedema. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.7850588.v1
title: Additional file 2: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S2. Results of gene ontology enrichment analysis. (XLSX 14 kb)
DOI: 10.6084/m9.figshare.7850570
title: Additional file 6: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S5. Table comparing annotation of all 75 ChrX escape candidates. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.7850576
title: Additional file 7: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S6. LncRNAs informative SNPs (iSNPs) along with their labeling on ChrX on both fibroblasts, and Lymphoblasts. (XLSX 70 kb)
DOI: 10.6084/m9.figshare.7850573
title: Additional file 13: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S13. Differentially expressed genes in mouse model of lymphedema. (XLSX 471 kb)
DOI: 10.6084/m9.figshare.7850579.v1
title: Additional file 14: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S14. Interactions of top 10 most promising candidate genes with genes/proteins associated with lymphedema. (XLSX 173 kb)
DOI: 10.6084/m9.figshare.7850564
title: Additional file 12: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S12. Frequency of mentioning analyzed gene names together with lymphedema in in full-text articles. (XLSX 13 kb)
DOI: 10.6084/m9.figshare.7850570.v1
title: Additional file 6: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S5. Table comparing annotation of all 75 ChrX escape candidates. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.7850564.v1
title: Additional file 12: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S12. Frequency of mentioning analyzed gene names together with lymphedema in in full-text articles. (XLSX 13 kb)
DOI: 10.6084/m9.figshare.7850573.v1
title: Additional file 13: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S13. Differentially expressed genes in mouse model of lymphedema. (XLSX 471 kb)
DOI: 10.6084/m9.figshare.7850549
title: Additional file 11: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S11. Results of prioritization according to criterion 5. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.7850561
title: Additional file 5: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S4. A list of informative SNPs (iSNPs) along with their labeling on ChrX, Chr17 and autosomes from single cell lymphoblasts and Pool100 lymphoblasts. (XLSX 5482 kb)
DOI: 10.6084/m9.figshare.7850552
title: Additional file 4: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S3. Gene-centric tagging determined by iSNPs and a read-based method for the Fibroblast, Lymphoblast and Pool100 datasets on ChrX, Chr17 and all autosomal chromosomes. (XLSX 2939 kb)
DOI: 10.6084/m9.figshare.7850549.v1
title: Additional file 11: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S11. Results of prioritization according to criterion 5. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.7850561.v1
title: Additional file 5: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S4. A list of informative SNPs (iSNPs) along with their labeling on ChrX, Chr17 and autosomes from single cell lymphoblasts and Pool100 lymphoblasts. (XLSX 5482 kb)
DOI: 10.6084/m9.figshare.7850537
title: Additional file 2: of Exome, transcriptome and miRNA analysis donâ t reveal any molecular markers of TKI efficacy in primary CML patients

description: Table S2. Pathways enriched with genes regulated by the selected miRNAs. (XLSX 11 kb)
DOI: 10.6084/m9.figshare.7850543
title: Additional file 10: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S10. Results of prioritization according to criterion 4B. (XLSX 16 kb)
DOI: 10.6084/m9.figshare.7850552.v1
title: Additional file 4: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S3. Gene-centric tagging determined by iSNPs and a read-based method for the Fibroblast, Lymphoblast and Pool100 datasets on ChrX, Chr17 and all autosomal chromosomes. (XLSX 2939 kb)
DOI: 10.6084/m9.figshare.7850534
title: Additional file 3: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S2. A list of informative SNPs (iSNPs) along with their labeling on ChrX, Chr17, all autosomal chromosomes and imprinted genes from 101 fibroblast single cells. (XLSX 60374 kb)
DOI: 10.6084/m9.figshare.7850537.v1
title: Additional file 2: of Exome, transcriptome and miRNA analysis donâ t reveal any molecular markers of TKI efficacy in primary CML patients

description: Table S2. Pathways enriched with genes regulated by the selected miRNAs. (XLSX 11 kb)
DOI: 10.6084/m9.figshare.7850525
title: Additional file 2: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S1. Quantitative data of primary fibroblast UCF_1014 cells and Identifiers and quantitative data of RNA-Seq for 25 lymphoid single cells and Pool100 (XLSX 18 kb)
DOI: 10.6084/m9.figshare.7850528
title: Additional file 1: of Exome, transcriptome and miRNA analysis donâ t reveal any molecular markers of TKI efficacy in primary CML patients

description: Table S1. List of primers. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.7850534.v1
title: Additional file 3: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S2. A list of informative SNPs (iSNPs) along with their labeling on ChrX, Chr17, all autosomal chromosomes and imprinted genes from 101 fibroblast single cells. (XLSX 60374 kb)
DOI: 10.6084/m9.figshare.7850543.v1
title: Additional file 10: of Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem

description: Table S10. Results of prioritization according to criterion 4B. (XLSX 16 kb)
DOI: 10.6084/m9.figshare.7850528.v1
title: Additional file 1: of Exome, transcriptome and miRNA analysis donâ t reveal any molecular markers of TKI efficacy in primary CML patients

description: Table S1. List of primers. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.7850525.v1
title: Additional file 2: of Human genes escaping X-inactivation revealed by single cell expression data

description: Table S1. Quantitative data of primary fibroblast UCF_1014 cells and Identifiers and quantitative data of RNA-Seq for 25 lymphoid single cells and Pool100 (XLSX 18 kb)
DOI: 10.25345/c5hn2g
title: MassIVE MSV000086031 - MassIVE_B_RP_LC_MS_MS Fatty Acid Identification
title: Sillner et al. : Longitudinal profiles of dietary and microbial metabolites in formula- and breastfed infants - https://doi.org/10.1101/2020.05.11.086546 Identification of fatty acids in infant fecal samples via RP LC-MS by MS1 (+-0.005Da) and retention time matching by the use of authentic standards and pooled samples - displayed in Figure 2A-C
DOI: 10.6084/m9.figshare.7850498
title: Additional file 7: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S7. Detailed PT distributions among drug ATC categories (XLS 66 kb)
DOI: 10.6084/m9.figshare.7850498.v1
title: Additional file 7: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S7. Detailed PT distributions among drug ATC categories (XLS 66 kb)
DOI: 10.6084/m9.figshare.7850489
title: Additional file 6: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S6. Overview of ATC second-level involved drugs (XLS 42 kb)
DOI: 10.6084/m9.figshare.7850477
title: Additional file 5: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S5. 1164 selected SPL documents used in this study. (XLS 378 kb)
DOI: 10.6084/m9.figshare.7850489.v1
title: Additional file 6: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S6. Overview of ATC second-level involved drugs (XLS 42 kb)
DOI: 10.6084/m9.figshare.7850477.v1
title: Additional file 5: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S5. 1164 selected SPL documents used in this study. (XLS 378 kb)
DOI: 10.6084/m9.figshare.7850468
title: Additional file 4: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S4. MedDRA term extraction performance of Oracle Text Search (XLS 56 kb)
DOI: 10.6084/m9.figshare.7850465
title: Additional file 3: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S3. Enriched cluster among ATC N categories (XLS 40 kb)
DOI: 10.6084/m9.figshare.7850462
title: Additional file 2: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S2. Drugs and PT distributions among MedDRA SOCs (XLS 33 kb)
DOI: 10.6084/m9.figshare.7850465.v1
title: Additional file 3: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

description: Table S3. Enriched cluster among ATC N categories (XLS 40 kb)